Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Diethylamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diethylamine SCHEMBL1524932 | 1.00 | ALOX15 (1.00) | ALOX15CYP3A4KDM4EMEN1TSHR | |
| Diethylamine SCHEMBL1524933 | 1.00 | ALOX15 (1.00) | ALOX15CYP3A4KDM4EMEN1TSHR | |
| SCHEMBL819207 | 0.88 | — | — | |
| SCHEMBL517340 | 0.88 | — | — | |
| SCHEMBL517339 | 0.88 | — | — | |
| SCHEMBL517338 | 0.88 | — | — | |
| SCHEMBL29394097 | 0.85 | ALOX15 (0.74) | ALOX15CYP3A4KDM4EMEN1TSHR | |
| SCHEMBL8089487 | 0.85 | ALOX15 (0.74) | ALOX15CYP3A4KDM4EMEN1TSHR | |
| SCHEMBL1374556 | 0.85 | ALOX15 (0.74) | ALOX15CYP3A4KDM4EMEN1TSHR | |
| SCHEMBL1525454 | 0.85 | ALOX15 (0.74) | ALOX15CYP3A4KDM4EMEN1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158359-A1 | HYDROLYSIS-RESISTANT ESTERS FOR DRUG AND IMAGING AGENT DELIVERY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-05-16 | — | — | US | disclosed |
| WO-2024095177-A1 | MANGANESE BIFUNCTIONAL CHELATING AGENT CONJUGATION PLATFORM FOR TARGETED MR IMAGING | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2024-05-10 | — | — | WO | disclosed |
| US-20240118204-A1 | Fluorescence Turn-On Detection of Nitric Oxide Free Radical Using a Simple Semiconducting Nanocrystal (QD) and Ferric Dithiocarbamate Complex | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE NAVY | 2024-04-11 | — | — | US | disclosed |
| US-20230285399-A1 | Compound for the treatment and prophylaxis of a lipofuscin-associated disease and/or a disease associated with aged oxidized melanin | KATAIRO GMBH (DE) | 2023-09-14 | — | — | US | disclosed |
| EP-4192445-A1 | COMPOUND FOR THE TREATMENT AND PROPHYLAXIS OF A LIPOFUSCIN-ASSOCIATED DISEASE AND/OR A DISEASE ASSOCIATED WITH AGED OXIDIZED MELANIN | Schraermeyer, Ulrich (DE) | 2023-06-14 | — | — | EP | disclosed |
| EP-2430014-A1 | ANTIVIRAL COMPOUNDS | Gilead Sciences, Inc. (US) | 2012-03-21 | — | — | EP | disclosed |
| EP-2429298-A2 | USE OF NO AND NO DONORS FOR TERMINATING DORMANCY IN INVERTEBRATES | Universiteit Gent (BE) | 2012-03-21 | — | — | EP | disclosed |
| US-20120064180-A1 | USE OF NO AND NO DONORS FOR TERMINATING DORMANCY IN INVERTEBRATES | UNIVERSITEIT GENT (BE) | 2012-03-15 | — | — | US | disclosed |
| WO-2010132601-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158359-A1 | HYDROLYSIS-RESISTANT ESTERS FOR DRUG AND IMAGING AGENT DELIVERY | ABCG2, BLVRB, CES1 | ALOX15 326/4885CYP3A4 152/4885KDM4E 770/4885 |
| US-20120064180-A1 | USE OF NO AND NO DONORS FOR TERMINATING DORMANCY IN INVERTEBRATES | NOS2, NOS1, NOS3 | ALOX15 462/4885CYP3A4 3176/4885KDM4E 2901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.